Next Generation Immune Checkpoint Modulators Market Research Report, Forecast to 2030

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

The USD 12 billion (by 2030) financial opportunity within the Next Generation Immune Checkpoint Modulators Market has been analyzed across the following segments:

Target Disease Indication

· Breast Cancer

· Chronic Lymphocytic Leukemia

· Colorectal Cancer

· Head and Neck Cancer

· Lung Cancer

· Lupus Nephritis

· Melanoma

· Multiple Myeloma

· Primary Sjögren's Syndrome

· Others

Target Immune Checkpoint

· B7-H3

· CD38

· CD40

· CD47

· Others

Mechanism of Action

· Inhibitory

· Stimulatory

Therapeutic Modality

· Monoclonal Antibody

· Small Molecule

· Type of Therapy

· Monotherapy

· Combination Therapy

· Route of Administration

· Intravenous

· Subcutaneous

· Others

Key Geographical Regions

· North America

· Europe

· Asia-Pacific and the Rest of the World

Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

· Bristol Myers Squibb

· GlaxoSmithKline

· Incyte

· Novartis

· Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape: Clinical and Preclinical Molecules

5. Market Landscape: Therapies Targeting Cd47

6. Market Landscape: Therapies Targeting 4-1bb

7. Clinical Trial Analysis

8. Company Profiles: Next Generation Inhibitors and Stimulators

9. Academic Grants Analysis

10. Partnerships and Collaborations

11. Target Competitiveness Analysis

12. Big Pharma Initiatives

13. Market Forecast and Opportunity Analysis

14. Concluding Remarks

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]